Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modified T cells (CAR Ts) is showing encouraging results...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhoj, Vijay G., Li, Lucy, Parvathaneni, Kalpana, Zhang, Zheng, Kacir, Stephen, Arhontoulis, Dimitrios, Zhou, Kenneth, McGettigan-Croce, Bevin, Nunez-Cruz, Selene, Gulendran, Gayathri, Boesteanu, Alina C., Johnson, Laura, Feldman, Michael D., Radaelli, Enrico, Mansfield, Keith, Nasrallah, MacLean, Goydel, Rebecca S., Peng, Haiyong, Rader, Christoph, Milone, Michael C., Siegel, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879023/
https://www.ncbi.nlm.nih.gov/pubmed/33614919
http://dx.doi.org/10.1016/j.omto.2021.01.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879023/
https://www.ncbi.nlm.nih.gov/pubmed/33614919
http://dx.doi.org/10.1016/j.omto.2021.01.012

Ejemplares similares